treatment

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan

TOKYO and CAMBRIDGE, Mass., Jan 16, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril(1) antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s... » read more

Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024

NEW YORK, NY, Jan 16, 2023 – (JCN Newswire via SEAPRWire.com) – PCG Digital — Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, is on track to deliver a safe and effective front-line treatment to a community of patients living with a rare, chronic cancer. [Image: Soligenix, Inc.] Cutaneous T-cell lymphoma (CTCL) is difficult to... » read more

AJG Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

ROCKVILLE, MD and SHENZHEN, CHINA, Nov 17, 2022 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in... » read more

American Journal of Gastroenterology Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

ROCKVILLE, MD and SHENZHEN, CHINA, Nov 16, 2022 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in... » read more

Zhaoke Ophthalmology’s Partner Vyluma Announces Positive Results from Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in Children

HONG KONG, Oct 28, 2022 – (ACN Newswire via SEAPRWire.com) – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or “the Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacturing and commercialization of treatments that address significant unmet medical needs, is pleased to announce that the Company’s partner Vyluma, Inc. (“Vyluma”) , a... » read more

BPipe Corporation, a Joint Venture Partner of Biopipe Global USA, enters into Agreement with Major Global Food Company to Install 10 m3/day Biopipe Biological Sewage Wastewater Treatment Plant

MANILA, Sep 27, 2022 – (ACN Newswire via SEAPRWire.com) – BPipe Corporation, an equity joint venture partner of Biopipe Global USA, enters into an agreement with a major global food company to install a 10 m3/day Biopipe biological sewage wastewater treatment plant. BPipe Corporation is focused on innovative, scalable and disruptive decentralized wastewater treatment and... » read more

ATAL’s Award-Winning AMSFS III Granted Patent in Mainland China

HONG KONG, Sep 15, 2022 – (ACN Newswire via SEAPRWire.com) – Analogue Holdings Limited (stock code: 1977) together with its subsidiaries (referred to as “ATAL Engineering Group”, “ATAL” or the “Group”), a leading electrical and mechanical (“E&M”) engineering services provider in Hong Kong, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted... » read more

Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA

HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 23... » read more

Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFa agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease

LAUSANNE, Switzerland, Aug 23, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (‘Oculis’) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, announces that the results of the double blinded, multicenter and placebo controlled Phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on... » read more

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

Continuously expanding the scope of potential indications for SN1011 HONG KONG, June 9, 2022 – (ACN Newswire) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is... » read more

Angelalign Announces 2021 Annual Results

HONG KONG, Mar 25, 2022 – (ACN Newswire via SEAPRWire.com) – Angelalign Technology Inc. (“Angelalign” or “Company”; stock code 6699) was pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2021 (the “Reporting Period”) today. In 2021, the company achieved robust business growth amid the market volatility... » read more

Memiontec Secures its Largest Contract to date following Award of a New S$56.6 Million Contract by PUB

Singapore, Mar 25, 2022 – (ACN Newswire via SEAPRWire.com) – Memiontec Holdings Ltd. (“Memiontec” or the “Company”, and together with its subsidiaries, the “Group”), a total water solutions provider in Asia, wishes to announce that the Group has been awarded a S$56.6 million contract (the “Contract”) by the Public Utilities Board (“PUB”), Singapore’s National Water... » read more

Japanese professor who pioneered advanced wastewater treatment wins LKY Water Prize

IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Approved by FDA

HONG KONG, Mar 14, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, the Investigational... » read more

IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA

HONG KONG, Feb 17, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 11... » read more

Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer’s Disease In The United States

TOKYO, Dec 21, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that, effective January 1, 2022, Biogen will reduce the wholesale acquisition cost (WAC) of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%. For a patient of average weight (74 kg), the yearly cost... » read more

Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia

TOKYO, Dec 20, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. today announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib (generic name, product name: Jyseleca), an oral, JAK1 preferential inhibitor for indications of rheumatoid arthritis (RA), ulcerative colitis, and Crohn’s disease in Asia... » read more

Gradiant Secures Five New DBOOM Projects in Indonesia and Vietnam, Appoints Managing Directors to Fuel Growth

Singapore, Dec 2, 2021 – (ACN Newswire via SEAPRWire.com) – Gradiant, a leading global cleantech water treatment solutions provider and projects developer, has announced the award of five design-build-own-operate-maintain (DBOOM) water treatment projects in Indonesia and Vietnam. Gradiant will provide end-to-end water treatment solutions through a customized approach using its proprietary suite of technologies to... » read more

Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension

TOKYO, Nov 11, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today results of new clinical, biomarker and safety assessments of brain amyloid reduction and five-year clinical status of people living with early Alzheimer’s disease (AD) from the lecanemab Phase 2b 201 and the open-label extension (OLE) studies. The... » read more

Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment

TOKYO, Oct 19, 2021 – (JCN Newswire via SEAPRWire.com) – Aichi Cancer Center (1) and Fujitsu Limited today announced the development of an AI solution able to select effective medical treatment from a wide range of drugs based on patients’ individual cancer types and various genomic variants (2). Figure1. The newly developed system The effectiveness... » read more